Table 3.
Studies of vaccine effectiveness in solid organ transplant patients
| Study | Results |
|---|---|
| Embi et al.83 Multistate analysis across 7 health care systems |
VE against COVID-19 associated hospitalization was lower (VE 77%) in immunocompromised patients compared with immunocompetent patients (VE 90%). VE was much lower (59%) in SOT and stem cell transplant patients. |
| Aslam et al.84 2151 SOT (912 vaccinated and 1239 controls) |
Infections occurred in 61 of unvaccinated vs 4 of fully vaccinated patients. Vaccination led to 80% reduction in the incidence of symptomatic COVID-19. |
| Ravanan et al.85 UK transplant registry Unvaccinated, n = 6748 Vaccinated, n = 39,727 |
The 28-d mortality rate was 12% in unvaccinated vs 7% in vaccinated individuals. |
| Malinis et al.86 Fully vaccinated SOT individuals, n = 459 |
Breakthrough infection occurred in 3/459 (0.65%) fully vaccinated individuals. |
| Anjan et al.87 Vaccinated SOT individuals (n = 2957) |
Breakthrough infections occurred in 26 patients (0.87%). 5 (19.2%) had severe COVID-19 and 2 (7.6%) patients died. |
| Qin et al.88 Fully vaccinated SOT individuals (n = 18,215) |
Breakthrough infections occurred in 151 patients (0.83%). Of those, 87 (0.48%) were hospitalized. Of those, 14 (0.077%) died. |
| Mehta et al.89 Fully vaccinated kidney transplant individuals (n = 1680) |
Breakthrough infections in 8 patients and 3 were hospitalized |
Abbreviation: VE, vaccine effectiveness.